Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

ClinicalTrials.gov ID: NCT02571036

Public ClinicalTrials.gov record NCT02571036. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients With Advanced Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.

Study identification

NCT ID
NCT02571036
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Enrollment
282 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2015 (Actual)
Primary completion
Apr 29, 2022 (Actual)
Completion
Apr 29, 2022 (Actual)
Last update posted
Dec 13, 2023

2015 – 2022

United States locations

U.S. sites
16
U.S. states
10
U.S. cities
13
Facility City State ZIP Site status
Honor Health (GIST, mastocytosis, other solid tumors) Scottsdale Arizona 85258 —
UCLA Hematology Center (mastocytosis) Los Angeles California 90024 —
UCLA (glial malignancies only) Los Angeles California 90095 —
Stanford University Comprehensive Cancer Center (GIST) Palo Alto California 94304 —
Stanford University Hematology Clinic (mastocytosis) Palo Alto California 94305 —
UCSF (glial malignancies only) San Francisco California 94143 —
Mayo Clinic (GIST, mastocytosis, glial malignancies, other solid tumors) Jacksonville Florida 32224 —
University of Miami (GIST, mastocytosis, glial malignancies, other solid tumors) Miami Florida 33136 —
Dana Farber Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors) Boston Massachusetts 02215 —
Colombia University Medical Center (mastocytosis) New York New York 10032 —
Memorial Sloan Kettering Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors) New York New York 10065 —
OHSU (GIST & mastocytosis only) Portland Oregon 97239 —
Fox Chase Cancer Center (GIST only) Philadelphia Pennsylvania 19111 —
MD Anderson Cancer Center (GIST, mastocytosis, glial malignancies, other solid tumors) Houston Texas 77030 —
Huntsman Cancer Institute (GIST, mastocytosis, glial malignancies, other solid tumors) Salt Lake City Utah 84103 —
Virginia Commonwealth University School of Medicine (mastocytosis) Richmond Virginia 23219 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02571036, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 13, 2023 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02571036 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →